Immunocore (IMCR) Set to Post Earnings on Thursday

Immunocore (NASDAQ:IMCR) is expected to be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.1751) per share and revenue of $152.28 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 2:00 AM ET.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative net margin of 4.20% and a negative return on equity of 4.54%.

Immunocore Price Performance

IMCR stock opened at $30.03 on Wednesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 4.44 and a current ratio of 4.47. The company’s fifty day moving average price is $32.09 and its 200-day moving average price is $31.78. Immunocore has a one year low of $27.50 and a one year high of $40.71. The company has a market capitalization of $1.55 billion, a PE ratio of -81.16 and a beta of 0.82.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a report on Monday, July 13th. Mizuho increased their price objective on shares of Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. TD Cowen raised shares of Immunocore to a “strong-buy” rating in a report on Monday, August 24th. Zacks Research lowered Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 3rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $55.86.

Immunocore Company Profile

Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.

The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.